Business Context and Reporting Period
Company: Danaher Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 3, 2009
Business Overview: Danaher is a multinational corporation operating in four segments: Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components. The company manufactures instrumentation, supply products, and services for life sciences, dental, product identification, environmental, and test and measurement markets.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Sales | $2,627.7 million | $3,028.9 million |
| Operating Profit | $340.2 million | $413.2 million |
| Net Earnings | $237.7 million | $276.5 million |
| Diluted EPS | $0.72 | $0.83 |
| Operating Margin | 12.9% | 13.6% |
| Gross Margin | 47.9% | 46.8% |
| Cash from Operations | $316.7 million | $333.2 million |
| Cash and Equivalents (Ending) | $975.9 million | $233.8 million |
| Total Debt (Long-term + Current) | $2,918.0 million | $2,619.0 million |
Material Changes vs. Prior Period
- Revenue Decline: Consolidated sales decreased 13% year-over-year. Sales from existing businesses declined 10%, driven by weak global demand and a 5.5% negative impact from currency translation due to a stronger U.S. dollar. Acquisitions contributed 2.5% growth.
- Profitability: Net earnings declined 14%. Operating profit margins compressed to 12.9% from 13.6%, primarily due to lower sales volumes reducing leverage on fixed costs, partially offset by cost savings from Q4 2008 restructuring.
- Liquidity Improvement: Cash and equivalents increased significantly from $392.9 million to $975.9 million. This was driven by a $745 million net proceeds from a new debt offering and strong operating cash flow, despite $50 million in cash payments for restructuring activities.
- Debt Structure: In March 2009, the company issued $750 million of 5.40% senior unsecured notes due 2019. Proceeds were used to repay commercial paper and for general corporate purposes.
Guidance, Outlook, and Risks
- Restructuring Actions: Management announced additional restructuring actions on April 21, 2009, to adjust the cost base due to continued weak demand. This plan involves pre-tax charges of up to $120 million (approx. $100 million employee-related, $20 million asset write-offs) and a net workforce reduction of approximately 2,300 associates. Total estimated restructuring costs for 2009 were revised to a range of $150 million to $170 million.
- Outlook: Management expects global demand to continue contracting, particularly in Industrial Technologies and Tools & Components segments. The company anticipates realizing annual pre-tax savings in excess of $100 million from Q4 2008 restructuring actions.
- Tax Rate: The effective tax rate for the remainder of 2009 is expected to be approximately 25%, influenced by the research and experimentation credit and a higher proportion of earnings in lower-tax foreign jurisdictions.
- Risks: Key risks include deteriorating global economic conditions, intense competition, foreign currency exchange rate fluctuations, and the potential for goodwill impairment charges if economic conditions worsen further.
Investor Verification Checklist
- Restructuring Impact: Verify the execution and cost of the newly announced $120 million restructuring plan and its impact on future operating margins.
- Currency Exposure: Monitor the strength of the U.S. dollar, as a stronger dollar is projected to adversely impact 2009 sales by approximately 4% relative to 2008 performance.
- Segment Performance: Review the divergence between segments; Medical Technologies showed resilience with low-single digit growth in some areas, while Industrial Technologies and Tools & Components faced double-digit declines.
- Debt Servicing: Confirm the impact of the new $750 million 5.40% notes on future interest expense, which is expected to be higher than Q1 2009 levels.
- Goodwill Valuation: Assess the risk of goodwill impairment given the $9.1 billion carrying value and the current global economic downturn.